🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Lineage Cell Therapeutics Inc (LCTX)

NYSE
Currency in USD
Disclaimer
0.910
+0.011(+1.11%)
Closed
After Hours
0.920+0.010(+1.099%)
LCTX Scorecard
Full Analysis
Analysts anticipate sales decline in the current year
Fair Value
Day's Range
0.9000.931
52 wk Range
0.7671.610
Prev. Close
0.899
Open
0.92
Day's Range
0.9-0.931
52 wk Range
0.767-1.61
Volume
206,518
Average Volume (3m)
490,591
1-Year Change
-31.06%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
LCTX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
5.000
Upside
+449.451%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year
Show more

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Compare LCTX to Peers and Sector

Metrics to compare
LCTX
Peers
Sector
Relationship
P/E Ratio
0.0x−3.3x−0.6x
PEG Ratio
0.00−0.040.00
Price/Book
0.0x1.4x2.6x
Price / LTM Sales
0.0x16.3x3.2x
Upside (Analyst Target)
0.0%516.8%41.1%
Fair Value Upside
Unlock23.0%5.9%Unlock

FAQ

What Is the Lineage Cell Therapeutics (LCTX) Stock Price Today?

The Lineage Cell Therapeutics stock price today is 0.91.

What Stock Exchange Does Lineage Cell Therapeutics Trade On?

Lineage Cell Therapeutics is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Lineage Cell Therapeutics?

The stock symbol for Lineage Cell Therapeutics is "LCTX."

What Is the Lineage Cell Therapeutics Market Cap?

As of today, Lineage Cell Therapeutics market cap is 171.84M.

What is Lineage Cell Therapeutics Earnings Per Share?

The Lineage Cell Therapeutics EPS is -0.134.

What Is the Next Lineage Cell Therapeutics Earnings Date?

Lineage Cell Therapeutics will release its next earnings report on 05 Nov 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.